Takeda Pharmaceuticals Company Limited (TYO: 4502) has announced the termination of a 2022 collaboration agreement with fellow Japanese firm JCR Pharmaceuticals Co., Ltd. (TYO: 4552) for the development of gene therapies. As a result of the termination, Takeda will return all research outcomes and patents to JCR. This strategic decision follows Takeda’s earlier move to refocus its development efforts away from adeno-associated virus (AAV) gene therapies, despite JCR’s recent pre-clinical proof-of-concept demonstrating the potential of its technology to function within the brain.
JCR, undeterred by the change in collaboration, is now set to independently advance its gene therapy initiatives and is actively exploring partnership opportunities with other companies to further its research and development efforts.- Fineline.com
